BioMarin Pharmaceutical (NASDAQ:BMRN) expects to file marketing applications in the U.S. and Europe in Q4 seeking approval for gene therapy valoctocogene roxaparvovec (VR) for the treatment of adults with severe hemophilia A.
VR has Breakthrough Therapy status in the U.S. and PRIME status in Europe.
Shares are off 1% premarket, albeit on only 100 shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.